Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Eleonora Cannas"'
Autor:
Chiara Tarantelli, David Wald, Nicolas Munz, Filippo Spriano, Alessio Bruscaggin, Eleonora Cannas, Luciano Cascione, Eugenio Gaudio, Alberto J. Arribas, Shivaprasad Manjappa, Gaetanina Golino, Lorenzo Scalise, Maria Teresa Cacciapuoti, Emanuele Zucca, Anastasios Stathis, Giorgio Inghirami, Patrick H. van Berkel, Davide Rossi, Paolo F. Caimi, Francesca Zammarchi, Francesco Bertoni
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Antibody-drug conjugates (ADCs) represent one of the most successful therapeutic approaches introduced in clinical practice in the last few years. Loncastuximab tesirine (ADCT-402) is a CD19 targeting ADC, in which the antibody is conjugated through
Externí odkaz:
https://doaj.org/article/0ddadfd5eefa4ca48941dd698807b5c9
Autor:
Chiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, Carmelo Moscatello, Eugenio Gaudio, Luciano Cascione, Sara Napoli, Cesare Rech, Andrea Testa, Chiara Maniaci, Andrea Rinaldi, Emanuele Zucca, Anastasios Stathis, Alessio Ciulli, Francesco Bertoni
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 2, Iss 6, Pp 586-601 (2021)
Aim: Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that play a fundamental role in transcription regulation. Preclinical and early clinical evidence sustain BET targeting as an anti-cancer approach. BET degraders are ch
Externí odkaz:
https://doaj.org/article/acda98a21cab4711808d202bf6f8291d
Autor:
Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas, Eugenio Gaudio, Chiara Tarantelli, Afua A. Mensah, Filippo Spriano, Antonella Zucchetto, Francesca M. Rossi, Andrea Rinaldi, Manuel Castro de Moura, Sandra Jovic, Roberta Bordone Pittau, Anastasios Stathis, Georg Stussi, Valter Gattei, Jennifer R. Brown, Manel Esteller, Emanuele Zucca, Davide Rossi, Francesco Bertoni
Publikováno v:
bioRxiv
BTK and PI3K inhibitors are among the drugs approved for the treatment of patients with lymphoid neoplasms. Although active, their ability to lead as single agents to long-lasting complete remission is rather limited especially in the lymphoma settin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::650dbcbfa343bf7d12bdb34071040c0f
https://europepmc.org/articles/PMC9881865/
https://europepmc.org/articles/PMC9881865/
Autor:
Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas, Eugenio Gaudio, Chiara Tarantelli, Afua A. Mensah, Filippo Spriano, Antonella Zucchetto, Francesca M. Rossi, Andrea Rinaldi, Manuel Castro de Moura, Anastasios Stathis, Georg Stussi, Valter Gattei, Jennifer R. Brown, Manel Esteller, Emanuele Zucca, Davide Rossi, Francesco Bertoni
Publikováno v:
Cancer Research. 83:394-394
Background: Marginal zone lymphoma (MZL) is an indolent yet incurable B cell malignancy. Two BTK inhibitors, ibrutinib and zanubrutinib, are FDA approved for relapsed/refractory MZL patients. PI3K inhibitors have also shown clinical activity. The ide